{"id":"W4400929921","doi":"10.1016/j.esmoop.2024.103646","title":"Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Incyte; Mirati Therapeutics; Jounce Therapeutics; Regeneron Pharmaceuticals; Daiichi-Sankyo; Amgen; Pfizer; EMD Serono; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tremelimumab; Durvalumab; Head and neck squamous-cell carcinoma; Medicine; CTLA-4; Oncology; PD-L1; Immunotherapy; Cytotoxic T cell; Internal medicine; Cancer research; Head and neck cancer; T cell; Immunology; Cancer; Immune system; Ipilimumab; Nivolumab; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002286334,0.001705649,0.002500261,0.0003684781,0.0004743008,0.001046379,0.001306276,0.001141111,0.001665006],"category_scores_gemma":[0.0008685626,0.0006621946,0.001465737,0.0004036497,0.001055272,0.0007976221,0.00034438,0.002521473,0.0006234882],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001486537,"about_ca_system_score_gemma":0.001888955,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001341897,"about_ca_topic_score_gemma":0.002680597,"domain_scores_codex":[0.9992429,0.0003552062,0.00003773997,0.0001446157,0.00008772563,0.0001318863],"domain_scores_gemma":[0.9991987,0.00009137822,0.0001902738,0.0000932662,0.00006128447,0.0003650234],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6506503,0.109321,0.01343491,0.0008561951,0.002918204,0.0004038923,0.0005107346,0.003181553,0.1187503,0.0001842374,0.002871963,0.09691679],"study_design_scores_gemma":[0.3520589,0.6150606,0.01936916,0.00003039936,0.001126292,0.0004386638,0.00008212183,0.001330467,0.008658016,0.0001007506,0.001706019,0.00003862733],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971488,0.0009871796,0.0002463193,0.0001149604,0.0000349078,0.0006951736,0.0003401707,0.00003878627,0.0003936521],"genre_scores_gemma":[0.9954398,0.0009766073,0.0007285414,0.0002563939,0.00009493071,0.0008381307,0.0009200571,0.00002210889,0.0007233784],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002500261,"threshold_uncertainty_score":0.0120914,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04684865456165723,"score_gpt":0.3826954400880829,"score_spread":0.3358467855264257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}